Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Evotec spin-off Breakpoint launches to develop anticancer drugs
by Ryan Cross
July 12, 2019
| A version of this story appeared in
Volume 97, Issue 28
A Hamburg, Germany–based start-up called Breakpoint Therapeutics has launched with $33.6 million to develop drugs that inhibit DNA-repair mechanisms. Breakpoint is a spin-off from the German contract research firm Evotec, which, along with Medicxi and Taiho Ventures, is funding the company. Breakpoint hopes that its compounds will deal a fatal blow to drug-resistant cancer cells. It wants to have a drug candidate ready for testing in 2022.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter